Cargando…
Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the...
Autores principales: | Schneider, Lon S., Qiu, Yuqi, Thomas, Ronald G., Evans, Carol, Jacobs, Diane M., Jin, Shelia, Kaye, Jeffrey A., LaCroix, Andrea Z., Messer, Karen, Salmon, David P., Sano, Mary, Schafer, Kimberly, Feldman, Howard H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/ https://www.ncbi.nlm.nih.gov/pubmed/34930444 http://dx.doi.org/10.1186/s13195-021-00938-w |
Ejemplares similares
-
Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS‐Cog‐Exec
por: Jacobs, Diane M., et al.
Publicado: (2020) -
Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association
por: Schneider, Lon S.
Publicado: (2015) -
Care plans for people with Alzheimer’s disease
por: Schneider, Lon S
Publicado: (2010) -
A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000) -
Composite cognitive and functional measures for early stage Alzheimer's disease trials
por: Schneider, Lon S., et al.
Publicado: (2020)